157 related articles for article (PubMed ID: 29113651)
1. The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer.
Amit A; Hodes A; Lavie O; Keidar Z; Matanes E; Lowenstein L
Surg Oncol; 2017 Dec; 26(4):347-351. PubMed ID: 29113651
[TBL] [Abstract][Full Text] [Related]
2. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
[TBL] [Abstract][Full Text] [Related]
3. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
4. The Value of PET-CT in Ovarian Epithelial Carcinoma: A Population-Based Study in British Columbia, Canada.
Cook SA; Wilson D; Pourghiasian M; Tinker AV
J Med Imaging Radiat Sci; 2020 Jun; 51(2):264-270. PubMed ID: 32113969
[TBL] [Abstract][Full Text] [Related]
5. The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL; Teixeira FR; Diniz TP; Faloppa CC; Mantoan H; da Costa AABA; Baiocchi G
J Gynecol Oncol; 2023 May; 34(3):e31. PubMed ID: 36731894
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study.
Gadducci A; Simonetti E; Manca G; Guidoccio F; Fanucchi A; Cosio S; Volterrani D
Anticancer Res; 2020 Apr; 40(4):2191-2197. PubMed ID: 32234914
[TBL] [Abstract][Full Text] [Related]
7.
García-Talavera P; Alejo E; Arias P; Verdú A; Tamayo P; Gómez-Caminero F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):207-213. PubMed ID: 34218882
[TBL] [Abstract][Full Text] [Related]
8. The value of [18F]FDG PET/CT examination in the detection and differentiation of recurrent ovarian cancer.
Kosinska M; Misiewicz P; Kalita K; Fijuth J; Foks M; Kuncman L; Gottwald L
Nucl Med Rev Cent East Eur; 2023; 26(0):98-105. PubMed ID: 37525539
[TBL] [Abstract][Full Text] [Related]
9. Assessment of peritoneal metastases with DW-MRI, CT, and FDG PET/CT before cytoreductive surgery for advanced stage epithelial ovarian cancer.
Mikkelsen MS; Petersen LK; Blaakaer J; Marinovskij E; Rosenkilde M; Andersen G; Bouchelouche K; Iversen LH
Eur J Surg Oncol; 2021 Aug; 47(8):2134-2141. PubMed ID: 33812768
[TBL] [Abstract][Full Text] [Related]
10. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
[TBL] [Abstract][Full Text] [Related]
11. The maximum standardized uptake value and extent of peritoneal involvement may predict the prognosis of patients with recurrent ovarian cancer after primary treatment: A retrospective clinical study.
Jiang Y; Hou G; Wu F; Zhu Z; Zhang W; Cheng W
Medicine (Baltimore); 2020 Feb; 99(8):e19228. PubMed ID: 32080121
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of 18F-FDG PET/CT-Based Models for Predicting Successful Complete Cytoreduction During Primary Cytoreductive Surgery for Advanced Ovarian cancer.
Kim J; Gil J; Kim SI; Hwangbo S; Noh JJ; Lee JW; Cheon GJ; Kim JW; Cho YS; Lee M
Clin Nucl Med; 2023 Feb; 48(2):e51-e59. PubMed ID: 36607373
[TBL] [Abstract][Full Text] [Related]
13. Role of
Abelleira E; García Falcone MG; Bueno F; Pitoia F
Endocrinol Diabetes Nutr (Engl Ed); 2020 Oct; 67(8):517-524. PubMed ID: 32534971
[TBL] [Abstract][Full Text] [Related]
14. Do PET-positive supradiaphragmatic lymph nodes predict overall survival or the success of primary surgery in patients with advanced ovarian cancer?
Braun C; Grünig H; Peikert J; Strobel K; Christmann-Schmid C; Brambs C
Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():13-19. PubMed ID: 38394714
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A multicentre study of the FRANCOGYN research group.
Delvallée J; Rossard L; Bendifallah S; Touboul C; Collinet P; Bricou A; Huchon C; Lavoue V; Body G; Ouldamer L
J Gynecol Obstet Hum Reprod; 2020 Nov; 49(9):101867. PubMed ID: 32663654
[TBL] [Abstract][Full Text] [Related]
16. FDG PET-CT in pediatric Langerhans cell histiocytosis.
Jessop S; Crudgington D; London K; Kellie S; Howman-Giles R
Pediatr Blood Cancer; 2020 Jan; 67(1):e28034. PubMed ID: 31599488
[TBL] [Abstract][Full Text] [Related]
17. [18F]FDG PET/CT and CA-125 in the evaluation of ovarian cancer relapse or persistence: is there any correlation?
Dondi F; Albano D; Bertagna F; Giubbini R
Nucl Med Rev Cent East Eur; 2022; 25(2):78-84. PubMed ID: 35848529
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of pre-treatment FDG-PET/CT staging of primary ovarian, fallopian tube, and peritoneal cancers in women.
Sponholtz SE; Mogensen O; Hildebrandt MG; Jensen PT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):186-195. PubMed ID: 31505027
[TBL] [Abstract][Full Text] [Related]
19. Molecular Imaging of Peritoneal Carcinomatosis in Ovarian Carcinoma.
Lee EYP; An H; Tse KY; Khong PL
AJR Am J Roentgenol; 2020 Aug; 215(2):305-312. PubMed ID: 32551907
[No Abstract] [Full Text] [Related]
20. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
Conte C; Marchetti C; Loverro M; Giudice MT; Rosati A; Gallotta V; Scambia G; Fagotti A
Int J Gynecol Cancer; 2023 Feb; 33(2):137-144. PubMed ID: 36639195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
